According to Clarity, 64Cu-SAR-bisPSMA demonstrates advantages over current diagnostic tools, including higher tumor uptake, next-day imaging, and longer half-life for PET imaging of PSMA-positive prostate cancer lesions.
FDA Grants Fast Track Designation to Clarity Pharmaceuticals’ Novel Treatment for PSMA-Positive Prostate Cancer Lesions
Leave a comment
